SLC5A2 and chronic kidney disease: The Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial showed that the SGLT2 inhibitor Dapagliflozin improved renal and cardiovascular outcomes in patients with CKD regardless of the presence of T2DM (12).